Short answer
Maze Therapeutics, Inc. (MAZE) filed an 8-K current report with the SEC on June 10, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). 89.75% shareholder participation provided a strong quorum for the 2026 annual meeting.
Maze Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.07 · Submission of Matters to a Vote of Security Holders
- 89.75% shareholder participation provided a strong quorum for the 2026 annual meeting
- Jason Coloma and Neil Kumar elected as Class I directors through the 2029 annual meeting
- Coloma received 35,792,536 votes for versus 5,926,467 withheld
- Kumar received 34,056,425 votes for versus 7,662,578 withheld
- Ernst & Young ratified as 2026 independent auditor with 44,557,778 votes for and 728 against
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Maze Therapeutics, Inc. 8-K filings
Get the next MAZE 8-K as it lands
Follow MAZE for push alerts, or ask the research agent what this filing means.